EDGAR Filing Documents for 0000950170-24-060556

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:

SEC Accession No. 0000950170-24-060556

Filing Date

2024-05-15

Accepted

2024-05-15 16:47:39

Documents

Period of Report

2024-03-31

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	10-Q	aktx-20240331.htm iXBRL	10-Q	1312304
2	EX-31.1	aktx-ex31_1.htm	EX-31.1	14338
3	EX-31.2	aktx-ex31_2.htm	EX-31.2	14295
4	EX-32.1	aktx-ex32_1.htm	EX-32.1	9945
5	EX-32.2	aktx-ex32_2.htm	EX-32.2	9464
	Complete submission text file	0000950170-24-060556.txt		6778302

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT	aktx-20240331.xsd	EX-101.SCH	1281886
62	EXTRACTED XBRL INSTANCE DOCUMENT	aktx-20240331_htm.xml	XML	1122625

Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210

Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702

Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 24952101
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)